contact[at]op2lysis.com

pilelabs
  • The company
  • The Technology
  • Products
  • Indications
  • News
  • Contact
  • Français

Monthly Archives: January 2022

  1. Home
  2. 2022
  3. January
  • adminop2lysis
  • January 2022
  • Corporate
A large number of successes in 2021!

You will find below a retrospective of 2021.

Read More

Articles récents

  • Retrospective – 2022 in a nutshell
  • The EIC Accelerator grant agreement has been signed by the European Innovation Council and provides €2.5M support to the O2L-001 development programme
  • Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission
  • Who are we? Meet Audrey Thiebaut – R&D Project Manager
  • A large number of successes in 2021!

Archives

  • January 2023
  • December 2022
  • September 2022
  • April 2022
  • January 2022

Catégories

  • Corporate
  • Press Release
gym-footer-logo

Biotechnology company that researches and develops innovative medicines

SItemap

  • Contact
  • home
  • Indications
  • Legal Notice
  • News
  • Products
  • The company
  • The Technology

Recent Posts

Retrospective – 2022 in a nutshell
January 24, 2023
The EIC Accelerator grant agreement has been signed by the European Innovation Council and provides €2.5M support to the O2L-001 development programme
December 07, 2022

Contact

  • FRANCE: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France BELGIUM: Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication